SMARTag® Technology: Modular Design Solutions for Best-in-Class ADCs

Summary: Catalent’s SMARTag® Technology offers a versatile and innovative platform for the development of optimized antibody-drug conjugates (ADCs). This proprietary, clinically tested technology, originally pioneered in the Bertozzi lab at UC Berkeley, enables site-specific conjugation that enhances ADC stability, scalability, and therapeutic index. By providing optimized linker-payloads, SMARTag® improves bioconjugate performance through enhanced cleavage activity and allows for flexibility in payload class, including the ability to incorporate multiple payloads on the same antibody at both equal and unequal ratios.

SMARTag® ensures superior pharmacokinetics, stability, and efficacy, making it the ideal choice for next-generation ADCs. The technology features modular linkers such as tandem-cleavage and branched linkers, enabling the generation of high-DAR conjugates and dual-payload ADCs. With a proven track record across clinical trials, SMARTag® accelerates the development of more effective and safer therapies for oncology and other complex diseases.

SMARTag® technology is accessible through discovery collaborations and is supported by our pipeline of discovery and preclinical assets. De novo discovery activities are conducted in Catalent’s state-of-the-art facility in Emeryville, CA, which is fully equipped with research-grade ADC manufacturing and testing capabilities.

Ready to learn more? Download our presentation to explore how SMARTag® technology can accelerate your ADC development and bring your innovative therapies to life.

Click here to download the Presentation